Literature DB >> 3053785

Synergistic regulation of human megakaryocyte development.

M W Long1, R J Hutchinson, L L Gragowski, C H Heffner, S G Emerson.   

Abstract

Little information exists concerning differing levels of regulation occurring during human megakaryocyte development. We hypothesize that megakaryocytic proliferation and maturation is controlled by two, synergistic regulatory factors. One, megakaryocyte colony-stimulating activity, is an obligate requirement for colony formation and drives the development of relatively immature cells. Megakaryocyte colony-stimulating activity is a functional component of the human recombinant proteins, interleukin 3 or GM-CSF. Human recombinant growth factors, interleukin 1, interleukin 6, or crythropoietin, do not effect megakaryocyte development either alone or in combination with interleukin 3. Full maturation requires a second synergistic activity which increases megakaryocyte number, size, and cytoplasmic and antigenic content. In culture, this synergistic regulator augments maturation by increasing the number of colonies, colony cellularity, and size. In suspension cultures, this cofactor increases megakaryocyte cytoplasmic and antigenic content, and shifts the morphological distribution from immature to mature megakaryocytes. Finally, this activity also increases the number of antigen positive megakaryocytes, either by stimulating proliferation or conversion of antigen-negative to antigen-positive cells. Comparative studies of megakaryocytic regulation suggests that this in vitro regulator mimicks some of the known effects of thrombopoietin in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3053785      PMCID: PMC442748          DOI: 10.1172/JCI113791

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Detection of human megakaryocyte antigens by solid-phase radioimmunoassay.

Authors:  M W Long; C H Heffner
Journal:  Exp Hematol       Date:  1988-01       Impact factor: 3.084

2.  Kinetics of thrombopoiesis.

Authors:  L A Harker
Journal:  J Clin Invest       Date:  1968-03       Impact factor: 14.808

3.  Regulation of thrombopoiesis.

Authors:  L A Harker
Journal:  Am J Physiol       Date:  1970-05

4.  Effects of thrombocytopenia on megakaryocytopoiesis.

Authors:  T T Odell; C W Jackson; T J Friday; D E Charsha
Journal:  Br J Haematol       Date:  1969-07       Impact factor: 6.998

5.  Detection of primitive macrophage progenitor cells in mouse bone marrow.

Authors:  T R Bradley; G S Hodgson
Journal:  Blood       Date:  1979-12       Impact factor: 22.113

Review 6.  Biology of megakaryocytes.

Authors:  S Ebbe
Journal:  Prog Hemost Thromb       Date:  1976

7.  Increasing stimulation of megakaryocytopoiesis with decreasing platelet count.

Authors:  T T Odell; C Shelton
Journal:  Proc Soc Exp Biol Med       Date:  1979-09

8.  Human marrow cells capable of erythropoietic differentiation in vitro: definition of three erythroid colony responses.

Authors:  C J Gregory; A C Eaves
Journal:  Blood       Date:  1977-06       Impact factor: 22.113

9.  Thrombokinetics in man.

Authors:  L A Harker; C A Finch
Journal:  J Clin Invest       Date:  1969-06       Impact factor: 14.808

10.  Role of I-region gene products in macrophage induction of an antibody response. II. Restriction at the level of T cell in recognition of I-J-subregion macrophage determinants.

Authors:  J E Niederhuber; P Allen
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

View more
  6 in total

1.  Regulation of megakaryocyte phenotype in human erythroleukemia cells.

Authors:  M W Long; C H Heffner; J L Williams; C Peters; E V Prochownik
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

2.  Expression of human bone-related proteins in the hematopoietic microenvironment.

Authors:  M W Long; J L Williams; K G Mann
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

3.  Preventive effects of interleukin 1 beta for ACNU-induced myelosuppression in malignant brain tumors: the experimental and preliminary clinical studies.

Authors:  S Tanaka; S Tabuchi; K Watanabe; H Takigawa; K Akatsuka; H Numata; Y Hokama; T Hori
Journal:  J Neurooncol       Date:  1992-10       Impact factor: 4.130

4.  Cloning and antisense oligodeoxynucleotide inhibition of a human homolog of cdc2 required in hematopoiesis.

Authors:  Y Lapidot-Lifson; D Patinkin; C A Prody; G Ehrlich; S Seidman; R Ben-Aziz; F Benseler; F Eckstein; H Zakut; H Soreq
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

5.  Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development.

Authors:  K Kaushansky; V C Broudy; N Lin; M J Jorgensen; J McCarty; N Fox; D Zucker-Franklin; C Lofton-Day
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

6.  Regulation of human bone marrow-derived osteoprogenitor cells by osteogenic growth factors.

Authors:  M W Long; J A Robinson; E A Ashcraft; K G Mann
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.